GI Onc Now Videos
PRECEDE offers testing for individuals at high risk of pancreatic cancer, with multiple testing sites located globally.
Dr. Rodón Ahnert compares the differences of sacituzumab tirumotecan use in the second- vs third-line setting for patients.
Dr. Goel discusses how his team's liquid biopsy can be used with CA19-9 to boost the accuracy of detecting pancreatic cancer.
Drs. Nataliya Uboha and Christopher Lieu highlight a recent analysis of the KRYSTAL-1 trial for metastatic colorectal cancer.
Dr. Ronan Kelly describes his trial on nivolumab with relatlimab for the treatment of resectable esophageal/GEJ cancer.
Dr. Gulam A. Manji discusses CXCR4 and PD-1 inhibitors and how research has shown a potential benefit of the combination.
Dr. Gulam A. Manji discusses the ARC-8 study on quemliclustat plus gemcitabine/nab-paclitaxel with and without zimberelimab.
Drs. White and Berman consider how the post hoc analysis of CROSSFIRE elucidates the benefit of ablative therapy with IO.
Drs. White and Berman share insights gained from the CROSSFIRE trial comparing IRE with SBRT in advanced pancreatic cancer.
Dr. William Jarnagin discusses his recent study on characterizing the heterogeneity of intrahepatic cholangiocarcinoma.
Dr. Kasi showcases NEST-1, a look at adverse events and downstaging effects from neoadjuvant bot/bal in pMMR/MSS CRC.
Dr. Kasi breaks down BESPOKE CRC, a tumor-informed ctDNA assay to inform adjuvant chemo treatment decisions in stage 2/3 CRC.
Dr. Christopher Lieu gives an overview of the BESPOKE trial and the GALAXY arm of CIRCULATE-Japan, as well as NETTER-2.
Dr. Pant discusses the relationship between T cell response magnitude and tumor biomarker reduction.
Dr. Janjigian discusses how the agent - created with invariant natural killer t-cells - works in tandem with other therapies.
Dr. Janjigian describes the history behind nivolumab treatment, and the differences in initial results versus follow-up.
Dr. Wainberg provides insight on the NAPOLI-3 study that compared NALIRIFOX against nab-paclitaxel plus gemcitabine.
Dr. Abou-Alfa describes the promising outcomes of infigratinib and delves into further research on FGFR alterations in CCA.
Dr. Eng discusses how fruquintinib differs from other VEGFR inhibitors.
Dr. Brooks explains the association between male sex and 5-FU exposure.
630 Madison Ave.
Manalapan, NJ 07726
© 2024 Mashup Media, LLC. All rights reserved.